Connect with us


Diabetes expert joins Glyconics as CMO

Avatar photo



Medtech firm Glyconics has appointed internationally renowned diabetes expert Dr Päivi Paldánius as its first Chief Medical Officer (CMO).

The move comes as it prepares to progress to its next clinical phase before embarking on a Series A funding round next year.

Glyconics exploits the ability of Infrared light to produce distinctive molecular ‘fingerprints’ for healthy vs non-healthy samples.

This is the first time IR spectroscopy has been miniaturised to deliver accurate results in minutes.

Dr Päivi Paldánius brings a wealth of experience and reputation from both the academic arena and a pharmaceutical career spanning two decades.

As a clinical scientist, she is best known for her principal clinical studies, INTERVAL and VERIFY, which have improved the practice of diabetic medicine worldwide and impacted various clinical guidelines.

Prior to joining Glyconics, she held various medical leadership positions at Novartis Pharma including worldwide executive medical director, director of global medical affairs (diabetes) and principle medical scientific expert (diabetes). She was also a lead protagonist in the development of the Time2DoMore in diabetes programme.

She said: “It is an enormous privilege for me to be working at Glyconics. I am passionate about improving ways to initiate, manage and optimise diabetes care, particularly for undiagnosed disadvantaged individuals in low to middle income countries. The fit with Glyconics is therefore highly beneficial.

“Glyconics offers a transformational cost-efficient, rapid and non-invasive approach to diabetes screening which will not require any plastic consumables.

“This is a huge opportunity to identify people at risk of diabetes and also save nature as well as, most importantly, combat the clinical inertia around the needs of individuals living with chronic disease, who don’t always get the focus and the optimised care they deserve.”

The company has also been awarded a coveted EU Seal of Excellence certificate for its technology developing a compact cost-effective way of using InfraRed (IR) Spectroscopy for point-of-care testing.

Until now, IR Spectroscopy could only be undertaken in a laboratory by highly trained staff.  And, last July, Glyconics was listed as one of the “80 standout European start-up pioneers driving seismic change in the post-pandemic world”.

Glyconics CEO, Dr Kam Pooni said: “We are thrilled to have Päivi joining our team. She is extremely well known and regarded in the diabetes world and is an important addition to our team at this stage of our development. With her expertise in clinical development, she is absolutely the right person to be taking Glyconics through this crucial clinical stage, and we all look forward to working with her.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories